---
title: Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome
nct_id: NCT04079426
overall_status: UNKNOWN
sponsor: University of Bonn
study_type: OBSERVATIONAL
primary_condition: Adult Respiratory Distress Syndrome
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04079426.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04079426"
ct_last_update_post_date: 2019-09-06
last_seen_at: "2026-05-12T07:32:58.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome

**Official Title:** Innate Immunity in Acute Respiratory Distress Syndrome: A Translational Approach to Limit Inflammasome-dependent Lung Inflammation by Tetracycline

**NCT ID:** [NCT04079426](https://clinicaltrials.gov/study/NCT04079426)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** University of Bonn
- **Conditions:** Adult Respiratory Distress Syndrome, Pneumonia, Sepsis
- **Start Date:** 2019-01-04
- **Completion Date:** 2022-01
- **CT.gov Last Update:** 2019-09-06

## Brief Summary

The acute respiratory distress syndrome (ARDS) is a severe form of respiratory failure with a mortality rate of approximately 40%. Despite advances in its supportive treatment such as lung protective ventilation or restrictive fluid management, no effective pharmacotherapy exists to treat ARDS. Emerging preclinical data indicates that excessive activation of the inflammasome-Caspase 1 pathway plays a key role in the development of ARDS. Tetracycline has anti-inflammatory properties via inhibiting inflammasome-caspase-1 activation. Since not much is known about the activation of the inflammasome in clinical ARDS, the purpose of this study is i) to investigate the the inflammasome-caspase-1 activation in clinical ARDS and ii) inhibit the innate immune response of alveolar leucocytes obtained by tetracycline from patients with ARDS

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \> 18 years
* Informed consent of the patient
* Diagnosis of ARDS for \< 48 h

Exclusion Criteria:

* Age \< 18 years
* Missing informed consent
* Immune therapy
* Autoimmune disease
```

## Interventions

- **Sampling of Blood and bronchoalveolar lavage** (OTHER) — Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.

## Primary Outcomes

- **Cytokine Levels in Serum and bronchoalveolar fluid** _(time frame: 1 week)_ — determined by multiplex Assay \[pg/ml\]
- **Activation Status of immune cells from blood and bronchoalveolar fluid** _(time frame: 1 week)_ — incubation of immune cells with tetracycline and Determination of cytokines by multiplex assay \[pg/ml\]
- **Alarmins in Serum and bronchoalveolar fluid** _(time frame: 1 week)_ — Determination by western blot, qPCR or flow cytometry

## Locations (1)

- University Hospital Bonn, Bonn, Germany — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital bonn|bonn||germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04079426.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04079426*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*